The Patent Finder
AR

Armagen, Inc.

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

5 patents currently held

8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2028. from the record

Of the 8 now held by other companies, 8 name JCR Pharmaceuticals Co. Ltd. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jul 2028
Next term end
3
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 69 later US patents, top 10% of utility patents granted in 2010 in our data. Protection runs to 2027.
Ends Aug 2027 · High confidence
Also notable
Cited by 48 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Ends Jun 2031 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

PatentTitleStatusExpiresConfidence
US 8,974,791Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS
In force
 · High confidence
In forceHigh confidence
US 11,512,145Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS
In force
 · High confidence
In forceHigh confidence
US 11,028,156Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS
In force
 · High confidence
In forceHigh confidence
US 12,043,661Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS
In force
 · High confidence
In forceHigh confidence
US 10,906,981Compositions and Methods Related to Structures That Cross the Blood Brain Barrier
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 5: 8 patents in force now held by others · 11 patents ended · 6 applications pending · 12 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited